NZ516261A - Mag expression promoters - Google Patents

Mag expression promoters

Info

Publication number
NZ516261A
NZ516261A NZ516261A NZ51626100A NZ516261A NZ 516261 A NZ516261 A NZ 516261A NZ 516261 A NZ516261 A NZ 516261A NZ 51626100 A NZ51626100 A NZ 51626100A NZ 516261 A NZ516261 A NZ 516261A
Authority
NZ
New Zealand
Prior art keywords
expression promoters
alkyl
mag expression
compounds
mag
Prior art date
Application number
NZ516261A
Other languages
English (en)
Inventor
Masakazu Kawasaki
Nobuharu Gotoh
Yoshiharu Hayashi
Kazuyuki Kawasaki
Original Assignee
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp
Publication of NZ516261A publication Critical patent/NZ516261A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
NZ516261A 1999-05-25 2000-05-25 Mag expression promoters NZ516261A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP14433699 1999-05-25
PCT/JP2000/003373 WO2000071119A1 (fr) 1999-05-25 2000-05-25 Promoteurs de l'expression de la glycoproteine associee a la myeline (mag)

Publications (1)

Publication Number Publication Date
NZ516261A true NZ516261A (en) 2003-11-28

Family

ID=15359751

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ516261A NZ516261A (en) 1999-05-25 2000-05-25 Mag expression promoters

Country Status (21)

Country Link
US (2) US7166630B2 (de)
EP (1) EP1186296B1 (de)
KR (1) KR100660955B1 (de)
CN (1) CN1160072C (de)
AT (1) ATE359780T1 (de)
AU (1) AU774471B2 (de)
BG (1) BG106254A (de)
BR (1) BR0011551A (de)
CA (1) CA2373967A1 (de)
CZ (1) CZ20014203A3 (de)
DE (1) DE60034448D1 (de)
EE (1) EE200100621A (de)
HK (1) HK1044721A1 (de)
HU (1) HUP0201485A3 (de)
IL (1) IL146726A0 (de)
IS (1) IS6173A (de)
MX (1) MXPA01012188A (de)
NO (1) NO20015733L (de)
NZ (1) NZ516261A (de)
RU (1) RU2241454C2 (de)
WO (1) WO2000071119A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1354664B1 (de) 2002-04-20 2010-11-17 Haas Laser GmbH & Co. KG Einrichtung zur Überwachung eines optischen Elements eines Bearbeitungskopfes einer Maschine zur thermischen Bearbeitung eines Werkstücks

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19541146A1 (de) 1995-10-25 1997-04-30 Schering Ag Imidazolderivate und deren Verwendung als Stickstoffmonoxid-Synthase-Inhibitoren
BR9612316A (pt) * 1995-12-27 1999-07-13 Yoshitomi Pharmaceutical Agente para profilaxia e tratamento de complicações diabéticas

Also Published As

Publication number Publication date
NO20015733L (no) 2002-01-11
MXPA01012188A (es) 2003-06-30
RU2241454C2 (ru) 2004-12-10
IL146726A0 (en) 2002-07-25
AU4949700A (en) 2000-12-12
WO2000071119A1 (fr) 2000-11-30
CZ20014203A3 (cs) 2002-06-12
HUP0201485A3 (en) 2004-01-28
BR0011551A (pt) 2002-04-02
HK1044721A1 (zh) 2002-11-01
AU774471B2 (en) 2004-07-01
EP1186296A4 (de) 2004-12-22
US20050090531A1 (en) 2005-04-28
EP1186296A1 (de) 2002-03-13
NO20015733D0 (no) 2001-11-23
ATE359780T1 (de) 2007-05-15
US7166630B2 (en) 2007-01-23
CN1356900A (zh) 2002-07-03
KR20020015332A (ko) 2002-02-27
CA2373967A1 (en) 2000-11-30
US20060270712A1 (en) 2006-11-30
EP1186296B1 (de) 2007-04-18
EE200100621A (et) 2003-02-17
DE60034448D1 (de) 2007-05-31
IS6173A (is) 2001-11-23
CN1160072C (zh) 2004-08-04
KR100660955B1 (ko) 2006-12-26
BG106254A (en) 2002-08-30
HUP0201485A2 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
ES2063289T3 (es) (2-imidazolin-2-ilamino) tetrahidroquinoxalinas y metodos para usarlas.
DE60336850D1 (en) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
HRP20050432A2 (en) Novel medicaments for the treatment of chronic obstructive pulmonary diseases
AP2088A (en) Phenethanolamine derivatives for treatment of respiratory diseases
NZ505362A (en) 4-hydroxyquinoline-3-carboxamides and -hydrazides useful as antiviral agents
MXPA03011981A (es) 3-fluoruro-pirrolidinas como agentes antidiabeticos.
HUP0204405A2 (en) Water soluble prodrugs of azole compounds
MXPA02007632A (es) Derivados de 2-benzotiazolil urea y su uso como inhibidores de proteina cinasa.
HRP20040371B1 (en) Thiopene- amd thiazolesulfonamides as antineoplastic agents
CA2282585A1 (en) Pyrazine compounds
MXPA05011207A (es) Uso de derivados de 2,4-dihidro-[1,2,4]triazol-3-tiona como inhibidores de la enzima mieloperoxidasa (mpo).
MY143353A (en) Diazole derivatives
MXPA04010055A (es) Derivados de tioxantina como inhibidores de mieloperoxidasa.
MXPA02004448A (es) Derivados de imidazopiridina como inhibidores de la fosfodiesterasa vii.
SE8900039L (sv) Isokinolinderivat, deras framstaellning och deras anvaendning
GEP20074045B (en) (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease
MXPA05005790A (es) Aminoalcoxiindoles como ligandos del receptor 5-ht6 para el tratamiento de enfermedades del sistema nervioso central.
ES8506652A1 (es) Un metodo de preparar dihidrobenzopirrolbenzodiazepinas
ES2180449A1 (es) Derivados de aril (o heteroaril) azolilcarbinoles para el tratamiento de la incontinencia urinaria.
NZ516261A (en) Mag expression promoters
CA2452036A1 (en) 6-'2-(phosphonomethoxy) alkoxy pyrimidine derivatives having antiviral activity
ATE308540T1 (de) Antithrombosemittel
DE60100314D1 (de) 7-carboxylatische flavon derivate, verfahren zur herstellung und verwendung als heilmittel
AU546260B2 (en) Diphenylbutyl-1-acylpiperazines
NZ533795A (en) Carboxamidine derivatives and their use in the treatment of vascular diseases

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
S38A Application for proceedings under section 38 (amendment of specification with leave of commissioner)

Free format text: BY WAY OF CORRECTION

S38C Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended
RENW Renewal (renewal fees accepted)